liqrev Drug Patent Profile

✉ Email this page to a colleague

When do Liqrev patents expire, and what generic alternatives are available?

Liqrev is a drug marketed by Cmp Dev Llc and is included in one NDA. There are four patents protecting this drug.

This drug has nine patent family members in nine countries.

The generic ingredient in LIQREV is sildenafil citrate. There are twenty drug master file entries for this compound. Sixty-eight suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Liqrev

A generic version of liqrev was approved as sildenafil citrate by CHARTWELL RX on November 6^th, 2012.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for liqrev?
What are the global sales for liqrev?
What is Average Wholesale Price for liqrev?

Summary for liqrev

International Patents:	9
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for liqrev
What excipients (inactive ingredients) are in liqrev?	liqrev excipients list
DailyMed Link:	liqrev at DailyMed

Drug patent expirations by year for liqrev

Pharmacology for liqrev

Drug Class	Phosphodiesterase 5 Inhibitor
Mechanism of Action	Phosphodiesterase 5 Inhibitors

US Patents and Regulatory Information for liqrev

liqrev is protected by four US patents.

Patents protecting liqrev

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: LIQREV IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS TO IMPROVE EXERCISE ABILITY AND DELAY CLINICAL WORSENING

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for liqrev

See the table below for patents covering liqrev around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Singapore	11202006080S	LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS	⤷ Sign Up
Canada	3086881	FORMULATIONS ORALES LIQUIDES POUR INHIBITEURS DE PDE V (LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS)	⤷ Sign Up
Morocco	50320	Formulations orales liquides pour inhibiteurs de pde v	⤷ Sign Up
Brazil	112020012986	formulações orais líquidas para inibidores de pde v	⤷ Sign Up
Japan	2021509114	ＰＤＥＶ阻害剤のための液体経口処方物	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for liqrev

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0463756	C990005	Netherlands	⤷ Sign Up	PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756	99C0007	Belgium	⤷ Sign Up	PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756	5/1999	Austria	⤷ Sign Up	PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622
0463756	SPC/GB99/004	United Kingdom	⤷ Sign Up	PRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

AI Research Assistant

Questions you can ask:

Summary for liqrev

Pharmacology for liqrev

Patents protecting liqrev

Make Better Decisions: Try a trial or see plans & pricing